Literature DB >> 12655310

GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice.

Victoria B Risbrough1, Jesse D Brodkin, Mark A Geyer.   

Abstract

The present experiments characterized the acquisition of fear-potentiated startle (FPS) and determined the sensitivity of FPS to anxiolytic compounds in DBA/1J mice. A light (30 s) conditioned stimulus (CS) and mild footshock (0.14 mA, 0.5 s) unconditioned stimulus (US) were used. First, acquisition of FPS was examined by presenting the acoustic startle probe during and after each CS-US pairing trial, allowing for a trial-by-trial measurement of experience-dependent startle plasticity. In this novel protocol, mice showed robust acquisition (larger acoustic startle reflex in the presence of the CS) of FPS after as few as eight CS-US pairings. FPS was significantly greater when the CS and US were paired explicitly (light-paired) as compared to when both the US and CS were presented randomly (unpaired), or when the CS was presented alone (no shock), indicating pairing-dependent learning of the CS. Second, the present study assessed the sensitivity of FPS in mice to anxiolytic drugs. The GABA-A receptor agonists diazepam (3 and 6 mg/kg) and chlordiazepoxide (10 mg/kg) significantly reduced the expression of FPS post-training, as did the serotonin 1A receptor partial agonist buspirone (5 and 10 mg/kg). Furthermore, all three anxiolytic drugs reduced startle responding in a cue-specific manner and without significant changes in baseline responding. These data demonstrate a novel method of studying acquisition of FPS, and support the predictive validity of the FPS model of anxiolytic drug action in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12655310     DOI: 10.1038/sj.npp.1300079

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  28 in total

1.  Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice.

Authors:  Kiersten S Smith; Edward G Meloni; Karyn M Myers; Ashlee Van't Veer; William A Carlezon; Uwe Rudolph
Journal:  Psychopharmacology (Berl)       Date:  2010-10-05       Impact factor: 4.530

2.  The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.

Authors:  Michel A Steiner; Hugues Lecourt; Francois Jenck
Journal:  Psychopharmacology (Berl)       Date:  2012-05-17       Impact factor: 4.530

3.  Olfactory-mediated fear conditioning in mice: simultaneous measurements of fear-potentiated startle and freezing.

Authors:  Seth V Jones; Scott A Heldt; Michael Davis; Kerry J Ressler
Journal:  Behav Neurosci       Date:  2005-02       Impact factor: 1.912

4.  Lesions of the habenula produce stress- and dopamine-dependent alterations in prepulse inhibition and locomotion.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  Brain Res       Date:  2006-01-24       Impact factor: 3.252

Review 5.  Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.

Authors:  Victoria B Risbrough; Murray B Stein
Journal:  Horm Behav       Date:  2006-07-25       Impact factor: 3.587

6.  Effects of alcohol on the acquisition and expression of fear-potentiated startle in mouse lines selectively bred for high and low alcohol preference.

Authors:  Gustavo D Barrenha; Laran E Coon; Julia A Chester
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

7.  Phenytoin normalizes exaggerated fear behavior in p-chlorophenylalanine (PCPA)-treated rats.

Authors:  Cathryn R Hughes; N Bradley Keele
Journal:  Epilepsy Behav       Date:  2006-10-12       Impact factor: 2.937

8.  Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration.

Authors:  Aaron Ettenberg; Rick E Bernardi
Journal:  Pharmacol Biochem Behav       Date:  2006-10-24       Impact factor: 3.533

9.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.

Authors:  Victoria B Risbrough; Richard L Hauger; Mary Ann Pelleymounter; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.